$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2015 Q3 Form 10-Q Financial Statement

#000119312515282067 Filed on August 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $6.300M $8.700M $7.300M
YoY Change -42.73% 19.18% -16.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.00M $14.60M $11.50M
YoY Change 61.62% 26.96% 98.28%
% of Gross Profit
Research & Development $68.62M $67.01M $44.67M
YoY Change 48.29% 50.0% 84.48%
% of Gross Profit
Depreciation & Amortization $5.300M $5.000M $2.900M
YoY Change 70.97% 72.41% 7.41%
% of Gross Profit
Operating Expenses $84.65M $81.63M $52.30M
YoY Change 50.71% 56.08% 74.34%
Operating Profit -$78.33M -$72.94M -$45.01M
YoY Change 73.3% 62.08% 111.17%
Interest Expense $1.600M $1.600M $700.0K
YoY Change 100.0% 128.57% 133.33%
% of Operating Profit
Other Income/Expense, Net $1.538M $1.592M $616.0K
YoY Change 20.44% 158.44% 137.84%
Pretax Income -$76.79M -$71.35M -$44.39M
YoY Change 74.84% 60.74% 110.84%
Income Tax $0.00 $400.0K -$300.0K
% Of Pretax Income
Net Earnings -$76.79M -$71.78M -$44.07M
YoY Change 74.57% 62.87% 142.58%
Net Earnings / Revenue -1218.92% -825.09% -603.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$907.8K -$850.7K -$581.8K
COMMON SHARES
Basic Shares Outstanding 84.62M shares 84.28M shares 75.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $977.6M $940.0M $605.3M
YoY Change 65.52% 55.29% 188.66%
Cash & Equivalents $149.2M $151.3M $80.73M
Short-Term Investments $828.4M $788.7M $524.6M
Other Short-Term Assets $17.50M $15.10M $10.30M
YoY Change 63.55% 46.6% 145.24%
Inventory
Prepaid Expenses
Receivables $8.100M $9.400M $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.042B $1.029B $665.1M
YoY Change 62.02% 54.73% 210.28%
LONG-TERM ASSETS
Property, Plant & Equipment $26.32M $25.17M $16.95M
YoY Change 39.93% 48.46% -6.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $358.6M $456.8M $350.6M
YoY Change 10.51% 30.29% 52.3%
Other Assets $9.400M $19.70M
YoY Change
Total Long-Term Assets $394.4M $501.6M $367.5M
YoY Change 14.86% 36.48% 48.08%
TOTAL ASSETS
Total Short-Term Assets $1.042B $1.029B $665.1M
Total Long-Term Assets $394.4M $501.6M $367.5M
Total Assets $1.436B $1.531B $1.033B
YoY Change 45.6% 48.24% 123.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.27M $15.72M $6.168M
YoY Change 174.41% 154.78% 36.04%
Accrued Expenses $18.44M $17.76M $15.78M
YoY Change -6.84% 12.51% 85.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.11M $66.60M $53.75M
YoY Change 0.46% 23.91% 1.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $57.40M $55.60M $1.000M
YoY Change 11380.0% 5460.0% -99.01%
Total Long-Term Liabilities $57.40M $55.60M $1.000M
YoY Change 11380.0% 5460.0% -99.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.11M $66.60M $53.75M
Total Long-Term Liabilities $57.40M $55.60M $1.000M
Total Liabilities $114.5M $122.2M $90.39M
YoY Change 39.89% 35.16% -41.45%
SHAREHOLDERS EQUITY
Retained Earnings -$1.156B -$1.079B -$891.3M
YoY Change 23.6% 21.09% 66.84%
Common Stock $2.485B $2.469B $1.812B
YoY Change 36.19% 36.29% 122.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.322B $1.409B $942.3M
YoY Change
Total Liabilities & Shareholders Equity $1.436B $1.531B $1.033B
YoY Change 45.6% 48.24% 123.25%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$76.79M -$71.78M -$44.07M
YoY Change 74.57% 62.87% 142.58%
Depreciation, Depletion And Amortization $5.300M $5.000M $2.900M
YoY Change 70.97% 72.41% 7.41%
Cash From Operating Activities -$54.40M -$55.40M -$46.60M
YoY Change 33.66% 18.88% 97.46%
INVESTING ACTIVITIES
Capital Expenditures -$6.500M -$1.300M -$1.800M
YoY Change 103.13% -27.78% 350.0%
Acquisitions
YoY Change
Other Investing Activities $55.20M -$105.7M -$226.5M
YoY Change 34.31% -53.33% 328.17%
Cash From Investing Activities $48.70M -$107.0M -$228.4M
YoY Change 28.16% -53.15% 329.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.600M 7.100M 5.100M
YoY Change -25.0% 39.22% 27.5%
NET CHANGE
Cash From Operating Activities -54.40M -55.40M -46.60M
Cash From Investing Activities 48.70M -107.0M -228.4M
Cash From Financing Activities 3.600M 7.100M 5.100M
Net Change In Cash -2.100M -155.3M -269.9M
YoY Change -200.0% -42.46% 270.74%
FREE CASH FLOW
Cash From Operating Activities -$54.40M -$55.40M -$46.60M
Capital Expenditures -$6.500M -$1.300M -$1.800M
Free Cash Flow -$47.90M -$54.10M -$44.80M
YoY Change 27.73% 20.76% 93.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18762000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84533778 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84533778 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
66598000
CY2015Q2 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
19654000
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
50256000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17758000
CY2015Q2 us-gaap Liabilities
Liabilities
122167000
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1011000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
845000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2468187000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
126000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12460000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53169000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77202753 shares
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
95.00
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
84615131 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80727000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1079190000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5313000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
1408604000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1530771000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
15715000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25169000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
456798000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
1029150000
CY2015Q2 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
64628000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151262000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1245538000
CY2015Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
9403000
CY2015Q2 us-gaap Assets
Assets
1530771000
CY2015Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
19654000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1265000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15117000
CY2015Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1246677000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
788740000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5011000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
936267000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77202753 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95334000
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
31667000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42983000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23680000
CY2014Q4 us-gaap Liabilities
Liabilities
143328000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1005000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
772000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1843362000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23871000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
48763000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-956630000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1079595000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15111000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21740000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
279821000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
746367000
CY2014Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
94583000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75179000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
806750000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
39937000
CY2014Q4 us-gaap Assets
Assets
1079595000
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
31667000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1121000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9739000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
807843000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
526929000
CY2014Q4 alny Facility Leases Future Minimum Payments Due
FacilityLeasesFutureMinimumPaymentsDue
459481000
CY2014Q4 alny Facility Leases Future Minimum Payments Due In Two Years
FacilityLeasesFutureMinimumPaymentsDueInTwoYears
11294000
CY2014Q4 alny Facility Leases Future Minimum Payments Due In Three Years
FacilityLeasesFutureMinimumPaymentsDueInThreeYears
13131000
CY2014Q4 alny Facility Leases Future Minimum Payments Due In Four Years
FacilityLeasesFutureMinimumPaymentsDueInFourYears
13055000
CY2014Q4 alny Facility Leases Future Minimum Payments Due In Five Years
FacilityLeasesFutureMinimumPaymentsDueInFiveYears
30954000
CY2014Q4 alny Facility Leases Future Minimum Payments Due Thereafter
FacilityLeasesFutureMinimumPaymentsDueThereafter
383182000
CY2014Q4 alny Facility Leases Future Minimum Payments Due Current
FacilityLeasesFutureMinimumPaymentsDueCurrent
7865000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8061000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-88300000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.11
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71833000 shares
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
768510000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-292751000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2240000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-159000
us-gaap Operating Income Loss
OperatingIncomeLoss
-314069000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4159000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-313202000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
15570000
us-gaap Investment Income Net
InvestmentIncomeNet
1026000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15703000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
867000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6360000
us-gaap Net Income Loss
NetIncomeLoss
-295017000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-332000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2266000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
187595000
us-gaap Operating Expenses
OperatingExpenses
329639000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
724013000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5468000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2235000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16679000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20443000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15090000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
723037000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27558000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-18185000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
121000
us-gaap Share Based Compensation
ShareBasedCompensation
13271000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-608155000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88430000
alny Research And Development Asset Acquired Through Other Than Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredThroughOtherThanBusinessCombinationWrittenOff
220766000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ALNY
dei Entity Central Index Key
EntityCentralIndexKey
0001178670
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8523000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-81711000
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 13%; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect&#xA0;the reported amounts of assets and liabilities and&#xA0;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&#xA0;the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83219000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
817670000
us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30001000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
496400000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
373068000
us-gaap Operating Expenses
OperatingExpenses
152388000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
606058000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8711000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-6909000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-152561000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3374000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
us-gaap Operating Income Loss
OperatingIncomeLoss
-125166000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-30534000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-122560000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
27222000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
288000
us-gaap Investment Income Net
InvestmentIncomeNet
2633000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
123000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2606000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5090000
us-gaap Net Income Loss
NetIncomeLoss
-122560000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-521000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
20763000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27346000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4138000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
89018000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
76083000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1195000
us-gaap Share Based Compensation
ShareBasedCompensation
18415000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-448264000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125042000
alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5447368 shares
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
496400000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21100000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75835000 shares
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47121000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45005000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44389000
CY2014Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7295000
CY2014Q2 us-gaap Investment Income Net
InvestmentIncomeNet
693000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
616000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-44074000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3047000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
52300000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11518000
CY2014Q2 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-315000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44672000
CY2014Q2 alny Research And Development Asset Acquired Through Other Than Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredThroughOtherThanBusinessCombinationWrittenOff
-3890000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84353000 shares
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-105406000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-72944000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-71352000
CY2015Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
8685000
CY2015Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1619000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1592000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-71783000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-33623000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
81629000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14622000
CY2015Q2 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
431000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67007000

Files In Submission

Name View Source Status
0001193125-15-282067-index-headers.html Edgar Link pending
0001193125-15-282067-index.html Edgar Link pending
0001193125-15-282067.txt Edgar Link pending
0001193125-15-282067-xbrl.zip Edgar Link pending
alny-20150630.xml Edgar Link completed
alny-20150630.xsd Edgar Link pending
alny-20150630_cal.xml Edgar Link unprocessable
alny-20150630_def.xml Edgar Link unprocessable
alny-20150630_lab.xml Edgar Link unprocessable
alny-20150630_pre.xml Edgar Link unprocessable
d939329d10q.htm Edgar Link pending
d939329dex101.htm Edgar Link pending
d939329dex102.htm Edgar Link pending
d939329dex103.htm Edgar Link pending
d939329dex104.htm Edgar Link pending
d939329dex105.htm Edgar Link pending
d939329dex106.htm Edgar Link pending
d939329dex107.htm Edgar Link pending
d939329dex311.htm Edgar Link pending
d939329dex312.htm Edgar Link pending
d939329dex321.htm Edgar Link pending
d939329dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g939329g62c85.jpg Edgar Link pending
g939329grapchi3.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending